Terms ending in 2041
Every in-force patent on Ipsen Biopharm Ltd.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,599,549 | Treatment of Moderate to Very Severe Glabellar Lines and Lateral Canthal Lines In force · High confidence | Galderma Holding S.A. | In force | High confidence | |
| US 12,642,842 | Therapeutic and Cosmetic Uses of Botulinum Neurotoxin Serotype E In force · High confidence | Ipsen Biopharm Limited | In force | High confidence | |
| US 11,975,055 | Suppression of Bone Cancer-induced Allodynia In force · High confidence | Ipsen Biopharm Limited | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.